First Clinical Medical College of Shanxi Medical University, No. 56 Xinjian South Road, Taiyuan, 030001, Shanxi, China.
Department of General Surgery, Jincheng General Hospital, Shanxi Medical University, Financial Street, Jincheng, 048006, Shanxi, China.
J Transl Med. 2024 Oct 28;22(1):971. doi: 10.1186/s12967-024-05771-x.
Breast cancer is the most common cancer type among women. Despite advanced treatment strategies, some patients still face challenges in disease control, prompting the exploration of new therapeutic approaches. N6-Methyladenosine (m6A) methylation modification regulates RNA and plays a crucial role in various tumor biological processes, closely linked to breast cancer occurrence, development, prognosis, and treatment. M6A regulators impact breast cancer progression, development, and drug resistance by modulating RNA metabolism and tumor-related pathways. Researchers have begun to understand the regulatory mechanisms of m6A methylation in breast cancer. This paper discusses the roles of m6A regulators in breast cancer progression, prognosis, and treatment, offering new perspectives for breast cancer diagnosis and treatment.
乳腺癌是女性中最常见的癌症类型。尽管治疗策略先进,但一些患者在疾病控制方面仍面临挑战,这促使人们探索新的治疗方法。N6-甲基腺苷(m6A)甲基化修饰调节 RNA,在各种肿瘤生物学过程中发挥着关键作用,与乳腺癌的发生、发展、预后和治疗密切相关。m6A 调节剂通过调节 RNA 代谢和肿瘤相关途径,影响乳腺癌的进展、发展和耐药性。研究人员已经开始了解 m6A 甲基化在乳腺癌中的调控机制。本文讨论了 m6A 调节剂在乳腺癌进展、预后和治疗中的作用,为乳腺癌的诊断和治疗提供了新的视角。